Sustainability of Brazilian policy for access to antiretroviral drugs

Bibliographic Details
Main Author: Grangeiro, Alexandre
Publication Date: 2006
Other Authors: Teixeira, Luciana, Bastos, Francisco I., Teixeira, Paulo
Format: Article
Language: por
eng
Source: Revista de Saúde Pública
Download full: https://www.revistas.usp.br/rsp/article/view/32012
Summary: OBJECTIVE: The expense of acquiring antiretroviral drugs in Brazil has given rise to debate about the sustainability of the policy of universal access to Aids medications, despite the evident benefits. The objective of this study was to analyze the evolution of the Ministry of Health's spending on acquiring antiretroviral drugs from 1998 to 2005, the determining factors and the medium-term sustainability of this policy (2006-2008). METHODS: The study on the evolution of spending on antiretrovirals included analysis of their prices, the year-by-year expenditure, the number of patients utilizing the medication, the mean expenditure per patient and the strategies for reducing the prices maintained during this period. To analyze the sustainability of the policy for access to antiretrovirals, the cost of acquiring the drugs over the period from 2006 to 2008 was estimated, along with the proportion of gross domestic product and federal health expenditure represented by this spending. The data were collected from the Ministry of Health, the Brazilian Institute for Geography and Statistics (IBGE) and the Ministry of Planning. RESULTS: The expenditure on antiretrovirals increased by 66% in 2005, breaking the declining trend observed over the period from 2000 to 2004. The main factors associated with this increase were the weakening of the national generics industry and the unsatisfactory results from the process of negotiating with pharmaceutical companies. CONCLUSIONS: The Brazilian policy for universal access is unsustainable at the present growth rates of the gross domestic product, unless the country compromises its investments in other fields.
id USP-23_e12e758a50bddae2443c207bc4ee0ef2
oai_identifier_str oai:revistas.usp.br:article/32012
network_acronym_str USP-23
network_name_str Revista de Saúde Pública
repository_id_str
spelling Sustainability of Brazilian policy for access to antiretroviral drugs Sustentabilidade da política de acesso a medicamentos anti-retrovirais no Brasil Agentes anti-HIV^i1^seconoAgentes anti-HIV^i1^sprovisão e distribuiPolítica de saúde^i1^seconoProgramas nacionais de saúde^i1^seconoGastos em saúde^i1^sestatística e dados numériCustos de cuidados de saúdeCustos de medicamentosPlanejamento socioeconômicoEconomia FarmacêuticaBrasilAnti-HIV agents^i2^seconomAnti-HIV agentes^i2^ssupply & distributuHealth policy^i2^seconomNational health programs^i2^seconomHealth expenditures^i2^sstatistics & numerical dHealth care costsDrug costsSocioeconomic planningEconomics^i2^spharmaceutiBrazil OBJECTIVE: The expense of acquiring antiretroviral drugs in Brazil has given rise to debate about the sustainability of the policy of universal access to Aids medications, despite the evident benefits. The objective of this study was to analyze the evolution of the Ministry of Health's spending on acquiring antiretroviral drugs from 1998 to 2005, the determining factors and the medium-term sustainability of this policy (2006-2008). METHODS: The study on the evolution of spending on antiretrovirals included analysis of their prices, the year-by-year expenditure, the number of patients utilizing the medication, the mean expenditure per patient and the strategies for reducing the prices maintained during this period. To analyze the sustainability of the policy for access to antiretrovirals, the cost of acquiring the drugs over the period from 2006 to 2008 was estimated, along with the proportion of gross domestic product and federal health expenditure represented by this spending. The data were collected from the Ministry of Health, the Brazilian Institute for Geography and Statistics (IBGE) and the Ministry of Planning. RESULTS: The expenditure on antiretrovirals increased by 66% in 2005, breaking the declining trend observed over the period from 2000 to 2004. The main factors associated with this increase were the weakening of the national generics industry and the unsatisfactory results from the process of negotiating with pharmaceutical companies. CONCLUSIONS: The Brazilian policy for universal access is unsustainable at the present growth rates of the gross domestic product, unless the country compromises its investments in other fields. OBJETIVO: Os gastos com a aquisição de anti-retrovirais no Brasil têm suscitado debates sobre a sustentabilidade da política de acesso universal a medicamentos para Aids, a despeito de seus evidentes benefícios. O objetivo do estudo foi analisar, no período de 1998 a 2005, a evolução dos gastos do Ministério da Saúde do Brasil com a aquisição de anti-retrovirais e seus determinantes, assim como a sustentabilidade desta política a médio prazo (2006-2008). MÉTODOS: O estudo da evolução dos gastos com anti-retrovirais compreendeu a análise de seus preços, do dispêndio ano a ano, do número de pacientes que utilizam a medicação, do gasto médio por paciente e das estratégias para a redução de preços adotadas no período. No tocante à análise de sustentabilidade da política de acesso a anti-retrovirais foram estimadas as despesas com a aquisição de medicamentos no período de 2006 e 2008 e a participação desses gastos no Produto Interno Bruto e nas despesas federais com saúde. Os dados foram coletados do Ministério da Saúde, do Instituto Brasileiro de Geografia e Estatística e do Ministério do Planejamento. RESULTADOS: As despesas com anti-retrovirais aumentaram 66% em 2005, interrompendo a tendência de redução observada no período 2000-2004. Os principais fatores associados a esse aumento foram o enfraquecimento da indústria nacional de genéricos e os resultados insatisfatórios dos processos de negociação com empresas farmacêuticas. CONCLUSÕES: A política de acesso universal no Brasil não é sustentável com as atuais taxas de crescimento do Produto Interno Bruto, sem que o País comprometa investimentos em outras áreas. Universidade de São Paulo. Faculdade de Saúde Pública2006-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://www.revistas.usp.br/rsp/article/view/3201210.1590/S0034-89102006000800009Revista de Saúde Pública; Vol. 40 No. supl. (2006); 60-69 Revista de Saúde Pública; Vol. 40 Núm. supl. (2006); 60-69 Revista de Saúde Pública; v. 40 n. supl. (2006); 60-69 1518-87870034-8910reponame:Revista de Saúde Públicainstname:Universidade de São Paulo (USP)instacron:USPporenghttps://www.revistas.usp.br/rsp/article/view/32012/34039https://www.revistas.usp.br/rsp/article/view/32012/34040Copyright (c) 2017 Revista de Saúde Públicainfo:eu-repo/semantics/openAccessGrangeiro, AlexandreTeixeira, LucianaBastos, Francisco I.Teixeira, Paulo2012-07-08T22:58:31Zoai:revistas.usp.br:article/32012Revistahttps://www.revistas.usp.br/rsp/indexONGhttps://www.revistas.usp.br/rsp/oairevsp@org.usp.br||revsp1@usp.br1518-87870034-8910opendoar:2012-07-08T22:58:31Revista de Saúde Pública - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Sustainability of Brazilian policy for access to antiretroviral drugs
Sustentabilidade da política de acesso a medicamentos anti-retrovirais no Brasil
title Sustainability of Brazilian policy for access to antiretroviral drugs
spellingShingle Sustainability of Brazilian policy for access to antiretroviral drugs
Grangeiro, Alexandre
Agentes anti-HIV^i1^secono
Agentes anti-HIV^i1^sprovisão e distribui
Política de saúde^i1^secono
Programas nacionais de saúde^i1^secono
Gastos em saúde^i1^sestatística e dados numéri
Custos de cuidados de saúde
Custos de medicamentos
Planejamento socioeconômico
Economia Farmacêutica
Brasil
Anti-HIV agents^i2^seconom
Anti-HIV agentes^i2^ssupply & distributu
Health policy^i2^seconom
National health programs^i2^seconom
Health expenditures^i2^sstatistics & numerical d
Health care costs
Drug costs
Socioeconomic planning
Economics^i2^spharmaceuti
Brazil
title_short Sustainability of Brazilian policy for access to antiretroviral drugs
title_full Sustainability of Brazilian policy for access to antiretroviral drugs
title_fullStr Sustainability of Brazilian policy for access to antiretroviral drugs
title_full_unstemmed Sustainability of Brazilian policy for access to antiretroviral drugs
title_sort Sustainability of Brazilian policy for access to antiretroviral drugs
author Grangeiro, Alexandre
author_facet Grangeiro, Alexandre
Teixeira, Luciana
Bastos, Francisco I.
Teixeira, Paulo
author_role author
author2 Teixeira, Luciana
Bastos, Francisco I.
Teixeira, Paulo
author2_role author
author
author
dc.contributor.author.fl_str_mv Grangeiro, Alexandre
Teixeira, Luciana
Bastos, Francisco I.
Teixeira, Paulo
dc.subject.por.fl_str_mv Agentes anti-HIV^i1^secono
Agentes anti-HIV^i1^sprovisão e distribui
Política de saúde^i1^secono
Programas nacionais de saúde^i1^secono
Gastos em saúde^i1^sestatística e dados numéri
Custos de cuidados de saúde
Custos de medicamentos
Planejamento socioeconômico
Economia Farmacêutica
Brasil
Anti-HIV agents^i2^seconom
Anti-HIV agentes^i2^ssupply & distributu
Health policy^i2^seconom
National health programs^i2^seconom
Health expenditures^i2^sstatistics & numerical d
Health care costs
Drug costs
Socioeconomic planning
Economics^i2^spharmaceuti
Brazil
topic Agentes anti-HIV^i1^secono
Agentes anti-HIV^i1^sprovisão e distribui
Política de saúde^i1^secono
Programas nacionais de saúde^i1^secono
Gastos em saúde^i1^sestatística e dados numéri
Custos de cuidados de saúde
Custos de medicamentos
Planejamento socioeconômico
Economia Farmacêutica
Brasil
Anti-HIV agents^i2^seconom
Anti-HIV agentes^i2^ssupply & distributu
Health policy^i2^seconom
National health programs^i2^seconom
Health expenditures^i2^sstatistics & numerical d
Health care costs
Drug costs
Socioeconomic planning
Economics^i2^spharmaceuti
Brazil
description OBJECTIVE: The expense of acquiring antiretroviral drugs in Brazil has given rise to debate about the sustainability of the policy of universal access to Aids medications, despite the evident benefits. The objective of this study was to analyze the evolution of the Ministry of Health's spending on acquiring antiretroviral drugs from 1998 to 2005, the determining factors and the medium-term sustainability of this policy (2006-2008). METHODS: The study on the evolution of spending on antiretrovirals included analysis of their prices, the year-by-year expenditure, the number of patients utilizing the medication, the mean expenditure per patient and the strategies for reducing the prices maintained during this period. To analyze the sustainability of the policy for access to antiretrovirals, the cost of acquiring the drugs over the period from 2006 to 2008 was estimated, along with the proportion of gross domestic product and federal health expenditure represented by this spending. The data were collected from the Ministry of Health, the Brazilian Institute for Geography and Statistics (IBGE) and the Ministry of Planning. RESULTS: The expenditure on antiretrovirals increased by 66% in 2005, breaking the declining trend observed over the period from 2000 to 2004. The main factors associated with this increase were the weakening of the national generics industry and the unsatisfactory results from the process of negotiating with pharmaceutical companies. CONCLUSIONS: The Brazilian policy for universal access is unsustainable at the present growth rates of the gross domestic product, unless the country compromises its investments in other fields.
publishDate 2006
dc.date.none.fl_str_mv 2006-04-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/rsp/article/view/32012
10.1590/S0034-89102006000800009
url https://www.revistas.usp.br/rsp/article/view/32012
identifier_str_mv 10.1590/S0034-89102006000800009
dc.language.iso.fl_str_mv por
eng
language por
eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/rsp/article/view/32012/34039
https://www.revistas.usp.br/rsp/article/view/32012/34040
dc.rights.driver.fl_str_mv Copyright (c) 2017 Revista de Saúde Pública
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2017 Revista de Saúde Pública
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Saúde Pública
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Saúde Pública
dc.source.none.fl_str_mv Revista de Saúde Pública; Vol. 40 No. supl. (2006); 60-69
Revista de Saúde Pública; Vol. 40 Núm. supl. (2006); 60-69
Revista de Saúde Pública; v. 40 n. supl. (2006); 60-69
1518-8787
0034-8910
reponame:Revista de Saúde Pública
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Revista de Saúde Pública
collection Revista de Saúde Pública
repository.name.fl_str_mv Revista de Saúde Pública - Universidade de São Paulo (USP)
repository.mail.fl_str_mv revsp@org.usp.br||revsp1@usp.br
_version_ 1800221784538087424